BOLT Lithotripsy RESTORE ATK Trial (RESTORE ATK)
BOLT Lithotripsy RESTORE ATK Trial for PAD (RESTORE ATK)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Graz, Austria
- Medical University of Graz
-
Vienna, Austria, 1090
- Universitätsklinik für Innere Medizin II
-
Vienna, Austria
- Mein Hanusch Krankenhaus
-
-
-
-
-
Split, Croatia
- University Hospital of Split
-
-
-
-
-
Arnsberg, Germany
- Klinikum Hochsauerland GmbH
-
Bad Krozingen, Germany
- Universitätsklinikum Freiburg Universitäts-Herzzentrum
-
Frankfurt, Germany, 60389
- MVZ CCB Frankfurt und Main-Taunus GbR
-
Frankfurt, Germany
- MVZ CCB Frankfurt und Main-Taunus GbR
-
Münster, Germany, 48149
- Universitätsklinikum Münster (UKM)
-
Münster, Germany, D-48145
- St. Franziskus-Hospital GmbH
-
Weinheim, Germany
- GRN Klinik Weinheim
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age of subject is ≥18.
- Rutherford Clinical Category 2, 3, or 4.
- Target lesion that is located in a native de novo superficial femoral artery (SFA) or popliteal artery (popliteal artery extends to and ends proximal to the ostium of the anterior tibial artery)
- Calcification is at least moderate. (presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending ≥ 50% the length of the lesion or absolute length ≥20mm.
Exclusion Criteria:
- Planned major amputation of the target leg (above the ankle)
- The use of chronic total occlusion (CTO) re-entry devices
- CTOs greater than 80 mm in length
- Lesions within 10 mm of ostium of the SFA
- Significant stenosis (>50% stenosis) or occlusion of inflow tract before target treatment zone (e.g., iliac or common femoral) not successfully treated with percutaneous angioplasty (PTA) or stent and without complications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intravascular lithotripsy
|
Enhancing percutaneous transluminal angioplasty by utilizing delivery of IVL to disrupt calcium in above the knee lesions prior to full balloon dilatation at low pressures
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Primary Effectiveness Endpoint
Time Frame: Immediately after the intervention/procedure/surgery
|
Post-treatment residual diameter stenosis of < 50% of the target lesion (with or without adjunctive PTA therapy and/or stenting)
|
Immediately after the intervention/procedure/surgery
|
|
Primary Safety Endpoint
Time Frame: Within 30 days following procedure
|
Composite of New-onset Major Adverse Events (MAEs)
|
Within 30 days following procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Freedom from Major Adverse Events (MAEs) within 6 months.
Time Frame: Within 6 months following procedure
|
Freedom from MAE within 6 months
|
Within 6 months following procedure
|
|
Residual diameter stenosis of <50% of the target lesion (without adjunctive PTA or stent therapy)
Time Frame: Immediately after the intervention/procedure/surgery
|
Residual diameter stenosis of <50% of the target lesion (without adjunctive PTA or stent therapy)
|
Immediately after the intervention/procedure/surgery
|
|
Residual diameter stenosis of <30% of the target lesion (without adjunctive PTA or stent therapy)
Time Frame: Immediately after the intervention/procedure/surgery
|
Residual diameter stenosis of <30% of the target lesion (without adjunctive PTA or stent
|
Immediately after the intervention/procedure/surgery
|
|
Target lesion patency - freedom from > 50% restenosis (assessed by DUS)
Time Frame: 30 days following procedure
|
Target lesion patency - freedom from > 50% restenosis (assessed by DUS)
|
30 days following procedure
|
|
Target lesion patency - freedom from > 50% restenosis (assessed by DUS)
Time Frame: 6 months following procedure
|
Target lesion patency - freedom from > 50% restenosis (assessed by DUS)
|
6 months following procedure
|
|
Freedom from Target Lesion Revascularization (TLR) at 6 months
Time Frame: 6 months following procedure
|
Freedom from Target Lesion Revascularization (TLR) at 6 months
|
6 months following procedure
|
|
Ankle-Brachial Index (ABI) of the target limb at all planned follow-up time points
Time Frame: at discharge after index procedure, 30 days following procedure, 6 months following procedure
|
Ankle-Brachial Index (ABI) of the target limb at all planned follow-up time points
|
at discharge after index procedure, 30 days following procedure, 6 months following procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TP-001701
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.